Placenta praevia
diseaseOn this page
Also known as placenta previa
Summary
Placenta praevia (MONDO:0005918) is a disease with 1 GWAS associations across 5 studies and 57 clinical trials. Top therapeutic interventions include hydroxyprogesterone caproate, nifedipine, and magnesium sulfate. A subtype of placenta disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- GWAS associations: 1
- Clinical trials: 57
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | placenta praevia |
| Mondo ID | MONDO:0005918 |
| EFO | EFO:0007442 |
| MeSH | D010923 |
| DOID | DOID:11060 |
| ICD-10-CM | O44 |
| NCIT | C26858 |
| SNOMED CT | 36813001 |
| UMLS | C0032046 |
| MedGen | 10782 |
| Is cancer (heuristic) | no |
Also known as: placenta praevia · placenta previa
Data availability: 1 GWAS association (5 studies).
Disease family
This is a subtype of placenta disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › reproductive system disorder › female reproductive system disorder › uterine disorder › placenta disorder › placenta praevia
Related subtypes (7): placental abruption, fetal growth restriction, oligohydramnios, placenta accreta, placental insufficiency, placenta neoplasm, disorder of extraembryonic membrane
Subtypes (1): low implantation of placenta
Genetics & variants
GWAS landscape
1 GWAS associations across 5 studies. Top hits map to 1 distinct genes (as reported by GWAS).
Top associations by p-value
| rsID | p-value | Gene | Risk allele | Odds ratio |
|---|---|---|---|---|
| rs145505746 | 9e-09 | PATJ | ? |
Top studies (by case count)
| Study | Lead author | Year | Cases | Controls | Title |
|---|---|---|---|---|---|
| GCST90454239 | Pujol Gualdo N | 2025 | 1,585 | 268,873 | Atlas of genetic and phenotypic associations across 42 female reproductive health diagnoses. |
| GCST90245829 | Changalidis AI | 2022 | 857 | 317,159 | Aggregation of Genome-Wide Association Data from FinnGen and UK Biobank Replicates Multiple Risk Loci for Pregnancy Complications. |
| GCST90651453 | Liu TY | 2025 | 367 | 123,916 | Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population. |
| GCST90727199 | Kim HI | 2026 | 303 | 43,723 | Exome sequencing and analysis of 44,028 British South Asians enriched for high autozygosity. |
| GCST90474239 | UK Biobank Whole-Genome Sequencing Consortium | 2025 | 211 | 458,229 | Whole-genome sequencing of 490,640 UK Biobank participants. |
Variant details and genetic-evidence tiers
Tier distribution (top 50 variants)
| Tier | Variants |
|---|---|
| Tier 1: coding | 0 |
| Tier 2: splice/UTR | 0 |
| Tier 3: regulatory | 0 |
| Tier 4: intronic/intergenic | 1 |
MAF distribution
| Bucket | Variants |
|---|---|
| common (>=0.05) | 0 |
| low_freq (0.01-0.05) | 0 |
| rare (<0.01) | 0 |
| unknown | 1 |
Functional consequences
| Consequence | Count |
|---|---|
| intron_variant | 1 |
Top variants
| rsID | Chr | Pos | Alleles | MAF | Consequence | Gene | p-value | Tier |
|---|---|---|---|---|---|---|---|---|
| rs145505746 | 1 | 61911307 | G>A | intron_variant | PATJ | 9e-09 | Tier 4: intronic/intergenic |
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
0 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.
| Drug | Development status |
|---|---|
| Magnesium Sulfate Anhydrous | Phase 3 (in late-stage trials) |
| Nifedipine | Phase 3 (in late-stage trials) |
| Tranexamic Acid | Phase 3 (in late-stage trials) |
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Progesterone.
Clinical trials & evidence
Clinical trials
Clinical trials: 57.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 47 |
| PHASE3 | 5 |
| PHASE2/PHASE3 | 2 |
| PHASE2 | 2 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05340205 | PHASE4 | COMPLETED | Blood Loss During Cesarean Delivery in Placenta Previa Patients |
| NCT07423156 | PHASE3 | NOT_YET_RECRUITING | Tranexamic Acid vs Vasopressin in Placenta Previa Trial |
| NCT01442207 | PHASE3 | WITHDRAWN | Cerclage for Prevention on Preterm Birth in Women With Placenta Previa |
| NCT03060889 | PHASE3 | COMPLETED | Tranexamic Acid Use in Elective Cesarean Section for Women With Placenta Previa |
| NCT03542552 | PHASE3 | COMPLETED | Nifedipine Versus Magnesium Sulfate for Prevention of Preterm Labor in Symptomatic Placenta Previa |
| NCT04055194 | PHASE2/PHASE3 | UNKNOWN | Antenatal Tranexamic Acid in Women With Symptomatic Placenta Previa |
| NCT04609527 | PHASE2/PHASE3 | UNKNOWN | Management of Placenta Accreta Spectrum |
| NCT05811676 | PHASE3 | COMPLETED | Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women With Placenta Previa |
| NCT00620724 | PHASE2 | COMPLETED | Tocolytic Therapy in Conservative Management of Symptomatic Placenta Previa |
| NCT03633175 | PHASE2 | UNKNOWN | Progesterone in Patients With Placenta Previa |
| NCT05802251 | Not specified | RECRUITING | Sonographic Parameters and Risk of Antepartum Hemorrhage in Asymptomatic Women With Placenta Previa: A Cohort Study |
| NCT06515535 | Not specified | NOT_YET_RECRUITING | Efficacy of Topical Tranexamic Acid in Reducing Blood Loss During CS in Patients With Placenta Previa |
| NCT06589180 | Not specified | NOT_YET_RECRUITING | Clinical Outcomes of Placenta Previa - an Individualized Scoring System |
| NCT06620068 | Not specified | NOT_YET_RECRUITING | Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study |
| NCT06867874 | Not specified | RECRUITING | Syncytiotrophoblast-derived Extracellular Vesicles in Placenta Previa and Accreta Spectrum |
| NCT06918236 | Not specified | RECRUITING | Association of Assisted Reproductive Technologies Parameters With the Perinatal Outcome |
| NCT07025954 | Not specified | RECRUITING | Planned Delivery at 37 Versus 36 Weeks in Pregnancies With Placenta Previaand Accreta |
| NCT07452185 | Not specified | NOT_YET_RECRUITING | Evaluation of Cervical Invasion and Length in Placenta Accreta Patients |
| NCT01289262 | Not specified | COMPLETED | Long Term Comparison of Two Different Techniques of Uterine Cesarean Incision Closure |
| NCT01990625 | Not specified | COMPLETED | A Cluster-Randomized Trial of Ultrasound Use to Improve Pregnancy Outcomes in Low Income Country Settings |
| NCT01996345 | Not specified | TERMINATED | Vaginal Pessary Versus Expectant Management for Placenta Previa |
| NCT02270593 | Not specified | UNKNOWN | ADAMTS,Proteoglycan and Oxidant / Antioxidant Enzyme Levels of Placenta Previa Totalis (Accreta, Increta, Percreta). |
| NCT02430038 | Not specified | COMPLETED | Transperineal Ultrasound to Assess the Progress of Labour |
| NCT02442518 | Not specified | UNKNOWN | Antenatal Diagnosis of Placental Attachment Disorders |
| NCT02590484 | Not specified | UNKNOWN | The Cervix as a Natural Tamponade in Postpartum Hemorrhage Caused by Placenta Previa and Placenta Previa Accreta |
| NCT02694341 | Not specified | WITHDRAWN | Bakri Balloon in Placenta Previa |
| NCT02966197 | Not specified | COMPLETED | Efficacy of Prophylactic Internal Iliac Artery Balloon Catheterization in the Management of Placenta Previa and Accreta |
| NCT03124472 | Not specified | UNKNOWN | Effect of Uterine Artery Ligation Prior to Uterine Incision in Women With Placenta Previa |
| NCT03208842 | Not specified | UNKNOWN | Relation of Implantation Site to Placental Site in Presence or Absence of Cesarean Section Scar |
| NCT03286998 | Not specified | UNKNOWN | Ultrasound in Prediction of Operative Findings in Cesarean Section Among Placenta Accreta Cases |
| NCT03321435 | Not specified | COMPLETED | The Placenta Previa and Fetal Weight |
| NCT03409822 | Not specified | COMPLETED | Non-invasive Hemoglobin Monitoring in Cesarean Section |
| NCT03431116 | Not specified | COMPLETED | Low Implanted Second Trimester Placenta and Placenta Previa |
| NCT03451136 | Not specified | UNKNOWN | Cervical Length in Cases of Placenta Previa |
| NCT03570723 | Not specified | COMPLETED | Glove-loaded Foley’s Catheter Tamponade for Cesarean Section for Placenta Previa |
| NCT03638024 | Not specified | UNKNOWN | Cell-free Fetal DNA Concentration in Cases of Abnormal Placental Invasion . |
| NCT03725553 | Not specified | COMPLETED | Intra-myometrial Vasopressin During Cesarean Section in Placenta Previa |
| NCT03741114 | Not specified | UNKNOWN | Foley’s Catheter Balloon Plus Tranexamic Acid During Cesarean Delivery for Placenta Previa |
| NCT03772184 | Not specified | COMPLETED | Modified Cervical Inversion During CS in Placenta Previa |
| NCT03774667 | Not specified | UNKNOWN | Characteristics, Complications and Perinatal Outcomes in Placenta Previa Women |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| HYDROXYPROGESTERONE CAPROATE | 4 | 2 |
| NIFEDIPINE | 4 | 2 |
| MAGNESIUM SULFATE | 4 | 1 |
| MISOPROSTOL | 4 | 1 |
| OXYTOCIN | 4 | 1 |
| VASOPRESSIN | 4 | 1 |
| CHEMBL4064157 | 0 | 1 |
| CHEMBL4303358 | 0 | 1 |
| MISOPROSTOL ACID | -1 | 1 |